About OmerosPipelineInvestorsNews

Investor Relations Home

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.64 (2.92%)
Data as of 07/27/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
06/29/17Omeros Releases Statement in Response to Recent False Report
SEATTLE--(BUSINESS WIRE)--Jun. 29, 2017-- Omeros Corporation (NASDAQ: OMER) stated today that it is aware of a report posted on-line by “Art Doyle,” an entity or group that appears to be concealing its identity and is purportedly writing on behalf of itself or one or more employers. “Art Doyle” self-identifies as having a short position in Omeros’ stock. While the company does not routinely respond to defamatory statements, given this report’s egregious ... 
 Printer Friendly Version
06/13/17FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy
- Omeros’ Second Phase 3 Clinical Program for OMS721 Slated to Begin this Year - SEATTLE--(BUSINESS WIRE)--Jun. 13, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP... 
 Printer Friendly Version
06/01/17Omeros Announces OMS721 Presentation at 54th ERA-EDTA Congress
SEATTLE--(BUSINESS WIRE)--Jun. 1, 2017-- Omeros Corporation (NASDAQ: OMER) today announced that data from the company’s Phase 2 clinical trial of OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy and other kidney diseases will be presented at the 54th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Madrid, Spain. The poster “The Effect of OMS721 on Proteinuria in Patients with IgA Nephropathy,” ... 
 Printer Friendly Version
05/17/17Omeros Announces Completion of IgA Nephropathy Cohort in OMS721 Phase 2 Clinical Trial
-- Additional Positive Results Support Rapid Advancement to Phase 3 Trial -- SEATTLE--(BUSINESS WIRE)--May 17, 2017-- Omeros Corporation (NASDAQ: OMER) today announced completion of the IgA nephropathy cohort and reported additional positive results from the first stage of the company’s Phase 2 clinical trial of OMS721 for the treatment of serious kidney disorders. All patients in the cohort have now completed the OMS721 treatment and follow-u... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation 2016 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.